|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> >> 市场分析报告 |
市场分析报告 |
|
Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide ... ) 14. GS-9669 (Company: Gilead Sciences) 15. GS-9190 (Tegobuvir) (Company: Gilead Sciences) 16. BMS-791325 ... 12. Setrobuvir (ANA-598) 13. VX-222 14. GS-9190 (Tegobuvir) 15. BMS-791325 Data Sources This ... KOL Insight: Hepatitis C: the Race for the First Interferon-free Regimen Analyzing the Hepatitis C Market Landscape After more than a decade of limited treatment options, the hepatitis C (HCV) market is on the cusp of a treatment revolution. In 2011, protease inhibitors-Incivek (telaprevir; Vertex) and Victrelis (boceprevir; ... Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight Approval of Gilead’s once daily oral nucleotide inhibitor Sovaldi marks a significant step in the treatment of hepatitis C (HCV). With efficacy over 90% in GT1/2/3/4 patients, this safe, best in class therapy represents a paradigm shift compared to the ... |